NXGL

NEXGEL, Inc.

$3.58

1.70%
SectorHealthcareIndustryMedical Instruments & SuppliesCountryUnited States

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also develops NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. It serves its customers under Medagel, Kenkoderm and Silly George brand names. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was incorporated in 2009 and is based in Langhorne, Pennsylvania.

Source: Yahoo Finance
AI summary

Price & performance

1M+28.7%
3M-47.0%
YTD-87.6%
1Y-90.5%
52-week range—
Beta0.84
Full chart and returns against a benchmark

Q-Score

31/ 100

Quality against peers; 50 is the peer median.

Growth46
Risk37
Performance27
Valuation50
Profitability37
Leverage24
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$11.4M+31.5%
Net income-$3M
Net margin-26.3%+11.5 pts
Historical fundamentals

Red flags in filings

4active red flags
Going-concern doubtMar 31, 2026
Material weakness in controlsMar 31, 2026
Late filing noticeAug 17, 2026
Filings, findings and the timeline

Revenue exposure

0%of revenue from outside the US
United States100%
Regions, segments, customers and suppliers

Valuation

NXGLIndustryP/E—49.36P/S0.143.73EV/EBITDA—23.12P/B0.353.92PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 16next report
EPS estimate$-4.80
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate